422 related articles for article (PubMed ID: 26620272)
1. Molecular therapy for acute myeloid leukaemia.
Coombs CC; Tallman MS; Levine RL
Nat Rev Clin Oncol; 2016 May; 13(5):305-18. PubMed ID: 26620272
[TBL] [Abstract][Full Text] [Related]
2. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
Verhaak RG; Goudswaard CS; van Putten W; Bijl MA; Sanders MA; Hugens W; Uitterlinden AG; Erpelinck CA; Delwel R; Löwenberg B; Valk PJ
Blood; 2005 Dec; 106(12):3747-54. PubMed ID: 16109776
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.
Falini B; Sportoletti P; Martelli MP
Curr Opin Oncol; 2009 Nov; 21(6):573-81. PubMed ID: 19770764
[TBL] [Abstract][Full Text] [Related]
4. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
DiNardo C; Lachowiez C
Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
[TBL] [Abstract][Full Text] [Related]
5. Incidence of FLT3 and nucleophosmin gene mutations in childhood acute myeloid leukemia: Serbian experience and the review of the literature.
Krstovski N; Tosic N; Janic D; Dokmanovic L; Kuzmanovic M; Spasovski V; Pavlovic S
Med Oncol; 2010 Sep; 27(3):640-5. PubMed ID: 19557552
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of combined IDH1 and NPM1 mutations in the intermediate cytogenetic de novo acute myeloid leukemia.
Abd El-Lateef AE; Ismail MM; Almohammadi M; Gawaly AM
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):92-98. PubMed ID: 34933728
[TBL] [Abstract][Full Text] [Related]
7. Evolving treatment strategies in patients with high-risk acute myeloid leukemia.
Schiller GJ
Leuk Lymphoma; 2014 Nov; 55(11):2438-48. PubMed ID: 24432896
[TBL] [Abstract][Full Text] [Related]
8. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.
Döhner K; Schlenk RF; Habdank M; Scholl C; Rücker FG; Corbacioglu A; Bullinger L; Fröhling S; Döhner H
Blood; 2005 Dec; 106(12):3740-6. PubMed ID: 16051734
[TBL] [Abstract][Full Text] [Related]
9. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
10. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetically Normal Acute Myeloid Leukaemia at a Single Centre in South Africa.
Jenkins N; Blanshard LA; Stone M; Verburgh E; Oosthuizen J; Shires K
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):397-406. PubMed ID: 37363984
[TBL] [Abstract][Full Text] [Related]
12. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
[TBL] [Abstract][Full Text] [Related]
13. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
Wen XM; Lin J; Yang J; Yao DM; Deng ZQ; Tang CY; Xiao GF; Yang L; Ma JC; Hu JB; Qian W; Qian J
Int J Clin Exp Pathol; 2014; 7(10):6832-40. PubMed ID: 25400766
[TBL] [Abstract][Full Text] [Related]
14. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
15. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
Miyashita N; Onozawa M; Yoshida S; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Hirabayashi S; Fujisawa S; Mori A; Ota S; Kakinoki Y; Tsutsumi Y; Yamamoto S; Miyagishima T; Nagashima T; Ibata M; Wakasa K; Haseyama Y; Fujimoto K; Ishihara T; Sakai H; Kondo T; Teshima T
Int J Hematol; 2023 Jul; 118(1):36-46. PubMed ID: 36853451
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
[TBL] [Abstract][Full Text] [Related]
18. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY
Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272
[TBL] [Abstract][Full Text] [Related]
19. Emerging molecular predictive and prognostic factors in acute myeloid leukemia.
McCurdy SR; Levis MJ
Leuk Lymphoma; 2018 Sep; 59(9):2021-2039. PubMed ID: 29095060
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.
Ostronoff F; Othus M; Lazenby M; Estey E; Appelbaum FR; Evans A; Godwin J; Gilkes A; Kopecky KJ; Burnett A; List AF; Fang M; Oehler VG; Petersdorf SH; Pogosova-Agadjanyan EL; Radich JP; Willman CL; Meshinchi S; Stirewalt DL
J Clin Oncol; 2015 Apr; 33(10):1157-64. PubMed ID: 25713434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
